You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

CLINICAL TRIALS PROFILE FOR CTP-692

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for CTP-692

Subscribe to access the full database, or Get Started Free
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03778320 ↗	A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers	Completed	Concert Pharmaceuticals	Phase 1	This study will assess the safety, tolerability and pharmacokinetic (PK) profile of CTP-692 vs D serine.
NCT03830463 ↗	Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers	Completed	Concert Pharmaceuticals	Phase 1	This study will assess the safety and pharmacokinetic (PK) profile of single ascending doses of CTP-692 in healthy volunteers.
NCT03880253 ↗	Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers	Completed	Concert Pharmaceuticals	Phase 1	This study will assess in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.
NCT04158687 ↗	A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia	Completed	Cognitive Research Corporation	Phase 2	The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily for 12 weeks to adult patients with schizophrenia on stable dopaminergic antipsychotic medication.
NCT04158687 ↗	A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia	Completed	Concert Pharmaceuticals	Phase 2	The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily for 12 weeks to adult patients with schizophrenia on stable dopaminergic antipsychotic medication.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for CTP-692

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Healthy	2
Healthy Volunteers	1
Schizophrenia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Schizophrenia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CTP-692

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	12
Australia	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	3
Texas	1
New York	1
New Jersey	1
Missouri	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CTP-692

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CTP-692

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Concert Pharmaceuticals	4
Cognitive Research Corporation	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.